Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The present resolution (75-100 A) of the conventional scanning electron microscope (SEM) and its ability to image the surfaces of large numbers of whole cells in situ permits the approach of problems such as viral and cell surface antigen localization by immunological labeling with visual markers. Identification of virus and cell surface antigens in situ has been accomplished in indirect reactions by conjugated and unconjugated markers. Hemocyanin (Hcy) from whelk, Busycon canniculatum, has been developed as an immunospecific marker for virion and cell surface labeling in the electron microscope. Its size (approximately 30 x 50 nm) and distinct cylindrical shape permit easy visualization in the SEM and TEM. The Hcy method involves the preparation of antisera to Hcy in appropriate hosts for use in an unlabeled antibody macromolecular procedure based exclusively on antigen-antibody affinity to couple the macromolecule to the antigen site. Further correlative data from fluorescence microscopy can be obtained from similarly labeled samples by binding fluorescein to the bridging antibodies used in the Hcy technique. The usefulness of the Hcy marker system was demonstrated using antisera to the major envelope and cell surface glycoprotein (gp70) of Rauscher murine leukemia virus (R-MuLV), a type C retrovirus. The antiserum was shown to bind to the virion and cell surfaces of virus-infected cells in the homologous virus-infected cell system. It also demonstrated the expression of R-MuLV gp70-related antigens on a murine cell line Mm5mt/c1 which produces mouse mammary tumor virus (MuMTV), A type B retrovirus. Furthermore, when used in the Hcy marker system this antiserum was able to distinguish type B from type C budding virus on the same cell. Examples of other marker systems (ferritin, peroxidase, colloidal gold, and latex) used to show anti-gp70 serum reactivity will be presented to demonstrate their applicability to cell surface labeling studies. Methods for the preparation of immunoreagents and labeling of cells are discussed.
 ...
PMID:Immunologic techniques for the identification of virion and cell surface antigens by correlative fluorescence, transmission electron and scanning electron microscopy. 39 19

The lymphoma cells from a patient with leukemia lymphoblastic sarcoma (Kiel classification) were observed by scanning and transmission electron microscopy. These cells were also examined by E, EA, EAC rosette-formation tests and by the indirect immunofluorescence technique for surface immunoglobulins. The malignant cells showed failure of rosette-formation or absence of surface immunoglobulins. Scanning electron microscopy revealed that many uniform protrusions were present on the cell surfaces. These surface protrusions were different from those seen on E-or EAC-rosette-forming cells. Ultrastructurally, the malignant cells were characterized by long profiles of rough surfaced endoplasmic reticulum with regular, narrow cisternae which radiated from Golgi area to the periphery of cytoplasm. These appearances differed from those observed in T-or B-lymphoma cells.
 ...
PMID:Scanning and transmission electronmicroscopy of leukemic lymphoma cells without T- and B-cell surface markers. 41 85

A series of halogeno (chloro or fluoro) analogues of phospholipid precursors has been checked for their cytostatic activity both in vitro and in vivo. The compounds included monoacyl-, diacyl-, monoalkyldeoxyhalogenoglycerols and other acylhalogenoalkanols. Analogues of monoacylglycerols or monoalkylglycerols were found to have a strong inhibitory activity on the proliferation of Ehrlich ascites carcinoma cells in suspension culture. The compounds were also effective in vivo. Tolerable doses (e.g. 1/10 of the LD50) given i.p. only once on the first day after transplantation of EAC cells reduced the cell number on day 7 by 99% or increased the survival time about 4-fold. The in vivo efficacy or the ether derivatives was higher than that of the corresponding esters. However, most of the compounds so far investigated had no effect on the survival time or cell number after s.c. application. Moreover, there was no prolongation of the survival time of leukemia L1210 or L184 bearing mice. This shows that the systemic effects of most of the compounds are low and that they have to come into direct contact with tumour cells during application in order to be active. It is discussed whether theese compounds interfere more with the structure of the membrane than with membrane biosynthesis. However, at least in comparison to Tween 80 (which is of poorer cytostatic activity) they show only very low lytic effects on red blood cells.
 ...
PMID:Inhibition of proliferation of Ehrlich ascites carcinoma cells in vitro and in vivo by halogeno analogues of long chain acyl- and alkylglycerols. 54 74

Investigation of the cell S--Ig in acute lymphocytic leukaemia (ALL), at the onset of relapse of the disease, shows quite marked differences from patient to patient according to the extent of the immunofluorescent-positive cells. They may vary from 0.5 to 25% or more. When these Ig-positive cells are treated with trypsin and then incubated "in vitro" for six hours, many of them are no longer Ig-positive, i.e. they do not synthesize Ig. It might be possible, that the membrane-Ig observed before trypsinization does not represent true Ig-determinants of mature B-cells (antibodies attached to leukaemia-specific determinants?). The extent of these features decrease in remission until their disappearance. Relationship between the cell immunological patterns and the treatment response in ALL could exist. In a group of ALL-patients under the same treatment, that is, vincristine and prednisone, the correlation between the course of the disease after the above-mentioned therapy showed quick and complete remission in patients with low percentage of Ig-positive cells (below 10%) and poor improvement (often without complete remission) in patients with higher percentage of Ig-positive cells. Among the most important B-lymphocyte abnormalities in chronic lymphocytic leukaemia (CLL) are the following: (a) fluorescence intensity may vary not only from patient to patient, but also from cell to cell in the same patient; (b) the Fc-receptor can be lacking; (c) the C3b-receptor is not always present, or it is from 2 to 20-folds less frequent than the C3d-receptor, whereas normal human lymphocytes do not show any outstanding differences between the number of EAC rosette-forming cells either when tested with mouse complement (C3d-receptor) or with human complement C3b-receptor); (d) the traffic capacity of peripheral-blood B-lymphocytes in CLL is quite defective. Results of the observations on lymphocytes in CLL, taken as a whole, suggest that CLL is in general given by the expansion of an abnormal clone of cells of B origin, arrested in their maturative development, non-responsive to the mitogen stimulation, accumulating in the peripheral-blood for a traffic deficiency. On the contrary, the T-cells class is apparently normal, and the T-cell extent in CLL-peripheral blood can be even greater than normal when taken as absolute value.
 ...
PMID:Lymphocyte immunological patterns in leukaemia: a review. 78 Feb 27

The clinical course of a patient with acute lymphoid immunoblastic leukaemia and prominent nodular haemorrhagic skin lesions is described. Cytological, cytochemical and electronmicroscopic studies were performed on bone marrow and skin blast cells. The absence of surface immunoglobulins and of the other markers for B lymphocytes (EA and EAC rosettes) and the presence of 30% of spontaneous sheep erythrocyte rosettes excluding an acute leukaemia with Burkitt's tumour cells, suggest that T cells are involved. Complete haematological and cutaneous remission was obtained with prednisone therapy.
 ...
PMID:Leucosis and skin: acute lymphoid immunoblastic leukaemia. 78 3

The peripheral blood cells of a patient with acute plasma cell leukemia were examined with transmission (TEM) and scanning (SEM) electron microscopes. The TEM features of the immature plasma cells comprised lobulated and irregulary shaped nuclei, with scanty heterochromating and bizarre nucleoli, parallel arrays of endoplasmic reticulum, cytoplasmic fibrils and numerous polymorphic mitochondria. SEM examination of the cells showed long, thin irregular ruffles, or round blebs on the cell surface, with appearance different from this observed on other types of leukemia. A remarkable clinical and hematological remission was achieved with administration of melphalan and steroids.
 ...
PMID:Transmission and scanning electron microscopy study on plasma cell leukemia. 89 Jan 42

B-, T- and O-lymphocytes detected as EAC-, E- and non-rosette forming lymphocytes were investigated in venous blood in 49 patients with connective tissue diseases, psoriasis and chronic lymphogenous leukaemia (CLL) during treatment with either prednisone alone, prednisone and cytostatic agents or cytostatic agents alone. Prednisone alone did not change the B-, T- and O-lymphocyte counts. Cytostatics alone or in combination with prednisone reduced the B- and T-lymphocyte counts concomitant with a significant increase in the O-lymphocyte count. The findings could be explained by assuming that cytostatics disturb the immunological functions of the lymphocytes and finally deprive the cells of their B- and T-markers. The optimal immunosuppressive treatment with cytostatic agents may be associated with a certain reduction of B- and T-lymphocytes which may be used as a guideline for dosage.
 ...
PMID:Influence of prednisone and cytostatics on human blood B-, T- and O-lymphocytes in diseases. 108 Dec 72

PHA stimulation of peripheral blood lymphocytes and/or leukemic cells has been studied in 65 patients with acute leukemia before any prior treatment. There were 38 patients with A.L.L. and 27 with A.M.L. In relapsing A.L.L. 15 observations were made before reinduction therapy. In about 40% of all the cultures PHA stimulation was done simultaneously with PWM-stimulation. Before any treatment normal lymphocytes showed a normal response, being however somewhat diminished at relapse. Most of the cases of A.M.L. had so many leukemic cells in peripheral blood that no reliable measure of stimulation of the few lymphocytes left was possible. In A.L.L. this was however possible in about 30% of all the cases studied. In cultures of the predominantly leukemic cells, lymphoblasts showed a positive response in a minority of cases studied. If the peripheral WBC-count was high, a response was usually absent. In some of the cases of A.M.L., the leukemic cells reacted to PHA and PWM. Unexpected but very remarkable is our finding that in the control cultures, without added mitogen, the incorporation of labelled 3H-thymidine was usually very high in A.M.L. contrasting with A.L.L. leukemic cells who incorporated very little of the label. These striking differences were observed both in 72 and 144 hours cultures and were not caused by differences in viability between these two leukemic cell-types. The capacity of A.L.L.-leukemic cells to form E ("T") and EAC ("B") rosettes was studied in 20 cases. The percentages of rosette forming lymphoblasts differed widely from patient to patient. It is concluded that in A.L.L. leukemic cells are in a minority immuno-competent cells and it is suggested that the lymphoblast is an immature cell, arrested in the maturation towards a T-lymphocyte, the degree of maturity differing from patient to patient. Furthermore the striking difference in spontaneous labelling of myeloid versus lymphoblastic leukemic cells seems to be helpful in the differential diagnosis and may in part explain the well known differences in prognosis and behaviour towards cytostatics between these main leukemia types.
 ...
PMID:T-cell qualities of lymphocytes and/or leukemic cells from peripheral blood in acute myeloid and lymphatic leukemia before treatment and at relapse. 108 49

Of four lactones studied in the systems Sa-180, EAC and L-1210, two compounds: alatolide, (ALA) and eupatoriopicrin (EUPP), according to the criteria of CCNSC, showed high cytostatic activity, and ursiniolide A (URSA) "moderate" cytostatic activity against at least one type of transplantable tumor. Two compounds were selected for further confirmatory investigation: EUPP, which gave 92% inhibition of EAC and 60% increase in survival of animals bearing Leukemia L-1210; and ALA, which gave 96% inhibition of growth of EAC.
 ...
PMID:Sesquiterpene lactones XVII. Cytostatic and pharmacological activity. 122 Jun 38

An isolate of Klebsiella oxytoca from the blood culture of a child with leukemia was found to produce two beta-lactamases, at least one of which conferred resistance to ceftazidime. Genes encoding both enzymes were located on a single self-transmissible 100-kb plasmid, pOZ201. This plasmid was introduced into Escherichia coli UB5201 (pACYC184), and the gene encoding one beta-lactamase was transposed onto plasmid pACYC184 by exploiting a gene dosage effect. The transposable gene was found to encode a TEM-12 enzyme as determined by nucleotide sequencing. This gene was subsequently transposed onto plasmid pUB307. The transposable element encoding the TEM-12 enzyme has been designated Tn841. Both plasmids pACYC184::Tn841 and pUB307::Tn841 were shown to encode a beta-lactamase with the same isoelectric point and substrate profile as the TEM-12 beta-lactamase. Transposon Tn841, at approximately 7 kb, is larger than TnA (4.8 kb) and transposes at a lower frequency. Although it produced a resolvase which can complement the resolvase of Tn3, its transposase function was not able to complement the transposition of a TnA element which lacked transposase. The occurrence of a gene encoding an extended-spectrum beta-lactamase on a transposable element in a clinically significant bacterium is potentially a cause for concern for the spread of resistance to the extended-spectrum cephalosporins.
 ...
PMID:Transposition of the gene encoding a TEM-12 extended-spectrum beta-lactamase. 132 36


<< Previous 1 2 3 4 5 6 7 Next >>